Introduction {#S1}
============

Rheumatoid arthritis is an immune mediated inflammatory disease characterized by autoantibody production \[including rheumatoid factor (RF) and anti--citrullinated protein antibody (ACPA), anti-carbamylated proteins antibodies (anti-CarP) etc.,\] chronic synovial inflammation (synovitis) and hyperplasia, cartilage and bone destruction, as well as systemic complications such as cardiovascular, pulmonary, and neurological co-morbidity. Progressive disability and systemic complications are still a burden leading to socioeconomic costs and unmet needs. Indeed, current conventional and biologic disease modifying therapies produce good responses in only 60% of patients ([@B48]). Predictive biomarkers of prognosis, therapeutic response, and resistance to treatment, which currently include ACPA, RF, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), remain inadequate from a clinical decision making perspective ([@B65]; [@B29]).

The loss of immune tolerance that precedes the onset of inflammation in the joint is thought to represent a key process in RA pathogenesis ([@B65]; [@B106]) and is likely to occur at extra-articular sites ([@B113]). Synovitis, the hallmark of established RA, is characterized by leukocyte infiltration, neo-angiogenesis and increased expression of adhesion molecules and chemokines which lead to increased leukocyte migration into the inflamed site. In addition, inadequate lymphangiogenesis, which limits cell egress, together with local fibroblast activation, promotes the establishment of synovial inflammation ([@B19]). Nutrient availability is also limited and immune and joint resident cells compete for available nutrients at a rate which exceeds their production thereby increasing the metabolic demand ([Figure 1](#F1){ref-type="fig"}; [@B36]; [@B114]; [@B81]; [@B7]; [@B115]; [@B125]; [@B130]). All these events can, in the long-term, induce an alteration of immune responses and promote a continued breach of immune tolerance leading to inflammation and autoimmunity.

![The inflammatory environment in RA synovium. The RA tissue microenvironment is characterized by the accumulation of cytokines, adipo-cytokines and metabolic intermediates produced by the accelerated metabolism of infiltrating and tissue resident immune cells. These events can promote or be the consequence of a dysregulation in several metabolic pathways (red), including glycolysis, TCA cycle, PPP and lipid metabolism, which regulate many cell functions including activation, differentiation, proliferation, autoantibody and cytokine production leading to pro-inflammatory immune responses and the exacerbation of chronic inflammation.](fphys-11-00347-g001){#F1}

Metabolites: A Focus on Lactate {#S2}
===============================

The study of intermediates and end-products of metabolism in the context of immune cell functions is an emerging field that has been termed immunometabolism ([@B82]). It is now clear that molecules such as succinate, lactate, acetyl-CoA, fumarate are more than intermediate by-products in metabolic pathways as they function as signaling molecules capable of linking metabolic reprograming with immune and inflammatory responses in immunity, inflammation and cancer ([Figure 1](#F1){ref-type="fig"}; [@B39]). Whether metabolic perturbations are causal or the effect of the disease and how they can impact on the prognosis of RA is an area of significant current research.

Nuclear magnetic resonance (NMR) spectroscopy--based metabolomics on serum and urine samples from people with RA has identified a metabolic signature of patients with active established RA which differs from that of healthy controls ([@B128]). Among the metabolites investigated 3-hydroxybutyrate and lactate were much higher in RA than in the control group. In addition choline, lactate and low-density lipoprotein (LDL) lipids strongly correlated with CRP a marker of disease activity ([@B128]). This evidence suggests that NMR could be used as a tool to predict the development of atherosclerosis and other metabolic complications often associated with inflammatory disease. Similarly, a gas chromatography--mass spectrometry (GC--MS) study on serum samples, has shown a decrease in amino acid and glucose metabolism in combination with increased fatty acid metabolites such as palmitate, oleate and cholesterol ([@B130]).

In the same vein, a correlation between serum metabolites and gene expression profiling in synovial tissue from patients with active RA was recently found ([@B71]). The authors described an association of serine, glycine, and phenylalanine metabolism with a lymphoid cell gene expression signature in synovial tissue. In addition, amino acids (i.e., alanine, aspartate, glutamate) and choline-derived metabolites correlated with TNF-α synovial expression while circulating ketone bodies associated with synovial gene expression of metalloproteinases. These data pointed to a link between serum metabolite profiles and synovial biomarkers further suggesting that NMR may be a promising technique for mapping pathogenic pathways in RA ([@B71]).

*In vitro* studies have further highlighted the role of metabolites as signaling molecules in mediating inflammatory responses. Studies on succinate have shown that lipopolysaccharides (LPS)-activated inflammatory (M1) macrophages accumulate this metabolite intracellularly as a consequence of an altered TCA cycle ([@B50]). Here succinate promotes the activation of hypoxia-inducible factor (HIF)-1α and increases pro-inflammatory interleukin (IL)-1β production. In addition, when activated by inflammatory stimuli, macrophages release succinate into the extracellular space and up-regulate G protein-coupled receptor (GPR)91, which functions as a sensor for extracellular succinate to enhance IL-1β production ([@B109]). Notably, GPR91-deficient mice display decreased macrophage activation and reduced IL-1β production during antigen-induced arthritis as well as decreased dendritic cell traffic and reduced differentiation of Th17 cells in the lymph nodes ([@B109]; [@B98]). High levels of succinate have been found in synovial fluid from RA patients, where it induces IL-1β release from macrophages in a GPR91-dependent manner. This evidence suggests that GPR91 antagonists may act as novel therapeutic molecules to treat RA ([@B60]). Interestingly, intracellular and extracellular succinate exhibit different functions. More specifically, intracellular succinate induces angiogenesis through HIF-1α, while extracellular succinate regulates GPR91 activation ([@B59]). The abolition of succinate dehydrogenase (SDH) activity with dimethyl malonate limited succinate accumulation and prevented angiogenesis via blocking the HIF-1α/VEGF axis, revealing a new potential therapeutic strategy to attenuate neo-angiogenesis in arthritis ([@B59]). If succinate exhibits pro-inflammatory activity, other metabolites such as fumarate and itaconate, have been observed to mediate anti-inflammatory effects ([@B64]; [@B68]). With regard to fumarate, the methyl ester dimethyl fumarate (DMF) has been approved for the treatment of relapsing multiple sclerosis (MS) ([@B32]; [@B37]). Interestingly DMF has been reported to reduce osteoclastogenesis and bone destruction *via* increasing the expression of nuclear factor erythroid 2--related factor 2 (NRF2)-mediated antioxidant genes and decreasing reactive oxygen species (ROS) levels ([@B122]). The role of itaconate in RA is still debated. Despite evidence suggests an anti-inflammatory role ([@B68]) other studies have shown that reduced levels of itaconate correlate with a decreased pro-inflammatory (M1) signature in human macrophages isolated from healthy control subjects ([@B78]) and with a reduced arthritis severity *in vivo* ([@B66]; [@B78]). It would be valuable to investigate how these observations in murine models translate into the human disease setting (i.e., OA vs. RA macrophages).

For more than 50 years, the inflamed joint has been recognized as a site with low levels of glucose and high amounts of lactate ([@B36]; [@B114]), as a consequence of the intense cellular turnover in the synovium. Accumulation of lactate in RA synovial fluid is in part responsible for the acidic environment of RA synovitis. Indeed, it is well established that the PH of synovial fluidis significantly lower in inflamed arthritic joints than in healthy joints ([@B23]).

The rheumatoid synovial environment is paradigmatic of some of the lactate-induced features seen in T cells, including IL-17 secretion and loss of antigen responsiveness ([@B20]). In particular, lactate modulates specific T cell subsets via the interaction with lactate transporters. Sodium lactate selectively affects CD4^+^ T cell functions via the solute carrier (SLC)5A12, while lactic acid was found to have an impact on CD8^+^ T cell motility and cytolytic capability via its influx through SLC16A1 (MCT1) ([@B40]; [@B88]).

Solute carrier 5A12 is highly expressed in RA synovial tissues and this expression significantly increases in association with the inflammatory T cell score ([@B40]; [@B88]). Notably we showed that SLC5A12 blockade promoted the egress of CD4^+^ T cell from the inflamed tissue in an organ culture model and improved clinical scores of disease in an experimental model of arthritis ([@B89]).

Another lactate transporter, the monocarboxylate transporter 4 (MCT4 or SLC16A3) was found to be up-regulated by RA synovial fibroblast (FLS) compared to osteoarthritis (OA) FLS ([@B34]). Silencing MCT4, with MCT4-specific siRNA, inhibited the proliferation of RA FLS and was able to reduce the severity of arthritis in mice with collagen-induced arthritis (CIA) ([@B34]).

These findings have established lactate signaling as integral feature of RA and open up the possibility of a new biomarker for disease progression and response to treatment as well as a novel target for therapeutic intervention. However, a better understanding of how the different synovial cell types co-ordinate their metabolism and the role of metabolites in cell-cell communication will be required to fully appreciate how the metabolic landscape in disease differs from that in health.

Glucose Metabolism {#S3}
==================

Proliferating cells mainly use aerobic glycolysis (Warburg effect) to generate energy. Indeed, in inflammatory conditions and tumors, aerobic glycolysis is preferred over oxidative phosphorylation for the production of ATP and for the stock of carbon sources necessary to build cell mass ([@B115]).

Both peripheral and tissue resident RA CD4^+^ T cells have a unique metabolic signature ([@B120]; [@B89]). Indeed, RA CD4^+^ T cells exhibit an impairment in engaging glycolysis. This is due to a deficiency of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3), a glycolysis regulator enzyme, resulting in delayed glycolysis and increased pentose phosphate pathway (PPP) via the up-regulation of glucose-6-phosphate dehydrogenase (G6PD). As a consequence, high levels of NADPH (reduced form nicotinamide adenine dinucleotide phosphate) and ROS consumption were observed. Moreover, altered activation of ataxia telangiectasia mutated (ATM), an enzyme involved in the cell cycle, was also reported. All these alterations result in increased cellular proliferation, a switch toward pro-inflammatory CD4^+^ T cell subsets (Th1 and Th17) and chronic inflammation ([@B124], [@B125]). Interestingly the replenishment of ROS was able to reverse these phenomena ([@B124], [@B125]). Similarly, CD4^+^ T cell from naive-to-treatment RA synovial tissues display a reduced expression of glycolytic genes coupled with increased PPP and Kreb cycle genes ([@B89]). These findings correlate with increased Th17 cell tissue infiltration and the formation of ectopic lymphoid structure (ELS) ([@B89]).

6-phosphofructo-2-kinase/fructose-2 deficiency also limits the ability of RA T cells to engage autophagy with increased susceptibility to apoptosis ([@B124]). This is linked with the recent discovery that RA T cells lack N-myristoyltransferase (NMT)-induced AMP-activated protein kinase (AMPK) activation which is a positive regulator of autophagy by suppressing the mammalian target of rapamycin (mTOR) activity ([@B53]; [@B14]; [@B119]). Further studies are needed to better comprehend the intracellular mechanisms linking metabolism, apoptosis, and autophagy in RA to understand potential therapeutic implications.

In contrast to T cells, RA FLS display increased glycolytic metabolism under metabolic stress ([@B31]). Indeed, glucose deprivation or glycolytic inhibitors \[i.e., 2-deoxy-[D]{.smallcaps}-glucose (2-DG)\], reduced FLS cytokine secretion, proliferation, and migration as well as disease severity in a mouse model of arthritis ([@B35]). In this context, RA FLS show an higher expression of the inducible isoform of hexokinase (HK)2, which catalyze the phosphorylation of glucose to glucose 6 phosphate (G6P), in comparison to OA FLS. Interestingly, HK2 silencing reduced RA FLS tissue invasiveness; by contrast, the overexpression of HK2 increased the levels of MMP, IL6, and IL8 along their migratory rate ([@B12]). These data were further confirmed *in vivo*, in a mouse model of arthritis, where the HK2 deletion in murine FLS ameliorated disease severity of arthritis ([@B12]). Similarly, the HK2 inhibitor, 3-bromopyruvate (BrPA), was found to modulate the Th17/Treg ratio and suppress dendritic cells (DC) activation and cytokine expression ([@B72]). In addition to its canonical role in glucose metabolism, HK2 translocates to mitochondria where it triggers an autophagic and anti-apoptotic responses through its interaction with the voltage-dependent anion channel (VDAC) ([@B108]). Intriguingly we found that lactate, which is abundant in the RA synovium, modulates HK2 mitochondrial translocation suggesting a potential role of this enzyme in promoting T cell survival. This provides an important link between metabolism and apoptosis resistance in the RA synovium that needs to be further explored ([@B89]).

Abnormal metabolism by RA FLS may be a consequence of the hypoxic microenvironment found in inflamed sites. Indeed, hypoxia by itself is able to induce a downregulation of mitochondrial respiration and an increase of glycolysis in RA fibroblasts, leading to synovial invasiveness, angiogenesis and synovial hyperplasia ([@B8], [@B7]). Moreover stimulation *in vitro* of RA FLS with platelet derived growth factor (PDGF) or TNF increased glucose metabolism ([@B35]).

Enhanced glycolysis is also observed in synovial monocytes and macrophages in RA. RA macrophages express high levels of the glycolytic enzyme α-enolase, which induces secretion of pro-inflammatory cytokines through autoantibody recognition ([@B3]). High concentrations of glucose have also been shown to increase IL-1β secretion from RA monocytes through an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3)/inflammasome-dependent mechanism ([@B94]) and the glycolytic enzyme HK1 is known to drive cleavage and activation of pro--IL-1β in macrophages ([@B69]). Following these results, a clinical trial (NCT02236481) has recently been published showing the efficacy of IL-1 inhibition, in terms of RA disease activity and glycated hemoglobin percentage (HbA1c%), as a targeted treatment in patients with RA and type 2 diabetes (T2D). Notably patients treated with TNF inhibitors did not achieve the same results (HbA1c reduction) in this trial suggesting a different pathogenic mechanism linking inflammation, T2D and RA. Further studies are needed to dissect the implication of NLRP3 and the risk of developing T2D in patients with RA ([@B96]) and to highlight the potential application of NLRP3-targeted therapies for these diseases. Driven by surrounding environmental conditions, glycolytic enzymes can translocate to the nucleus ("moonlighting"), where they regulate the expression of their target mRNAs and modulate immune responses ([@B27]; [@B10]). For instance, the glycolytic enzyme pyruvate kinase M2 (PKM2) plays a crucial role in the regulation of transcription factors and cytokine production in both coronary artery disease (CAD) and RA macrophages ([@B104]; [@B120]). Specifically, increased ROS production during inflammation, promotes PKM2 dimerization enabling its nuclear translocation and transcription factor STAT3 phosphorylation, thereby enhancing IL-6 and IL-1β production ([@B104]; [@B120]). Reducing glycolysis, limiting superoxide production and promoting PKM2 tetramerization, repaired the pro-inflammatory phenotype of CAD macrophages ([@B104]). Similarly we found that lactate induces the nuclear translocation of PKM2 in activated CD4^+^ T cells, boosting IL-17 production in a STAT3 dependent manner ([@B89]).

Emerging evidence suggests that hypoxia and HIFs play a pivotal role in the regulation of several pathophysiological features of RA including synovitis, angiogenesis, and cartilage destruction ([@B47]). In particular, HIF-1α, a master regulator of glycolysis, is highly expressed by macrophages in the RA synovium, compared to macrophages in OA and healthy control synovium ([@B46]) suggesting HIF-1α as novel potential therapeutic target. It will be interesting to determine whether these observations reflect up or down regulation of HIF-1α in the same macrophage subset in RA and OA or alternatively is a reflection of different subsets of macrophages in RA and OA ([@B19]).

Vascular endothelial growth factor-dependent HIF-1α pathways play a key role in endothelial cell (EC) metabolism. Indeed, in response to growth factor stimulation, such as by vascular endothelial growth factor (VEGF), EC become highly activated, proliferative, and acquire migratory capability ([@B86]; [@B117]) with increased glycolysis ([@B126]; [@B80]; [@B26]). Blockade of the glycolytic enzyme, PFKFB3, inhibited angiogenic tube formation *in vivo* and reduced the secretion of pro-inflammatory/angiogenic mediators in RA FLS and EC suggesting a key role of this glycolytic enzyme in promoting angiogenesis and inflammation ([@B7]). G6PI was also found to be important in the regulation of VEGF secretion from RA FLS ([@B61]). Indeed, in hypoxic conditions, both G6PI and HIF-1α were increased. This phenomenon was accompanied by enhanced proliferation of RA FLS and angiogenic tube formation of human dermal microvascular endothelial cells (HDMECs) *in vivo*. These events were reversed in G6PI loss-of-function experiments, thus confirming the requirement for G6PI in promoting angiogenesis in RA ([@B61]).

Mitochondrial Metabolism {#S4}
========================

Mitochondrial functions in RA are still under investigation. Mitochondrial DNA (mtDNA) mutations and ROS production were found to be higher in RA compared to OA FLS ([@B24]). In addition, they correlated with elevated MMP expression and a more invasive phenotype of FLS ([@B43]). Another study showed that mitochondria in macrophages isolated from the RA synovium, produced more ATP, consumed more oxygen and developed inter-organelle connections with the endoplasmic reticulum, forming mitochondria-associated membranes (MAM). MAMs promote mitochondrial hyperactivity and calcium transport, and induce the inactivation of glycogen synthase kinase 3b (GSK3b). In turn, the inactivation of GSK3b increases the production of the collagenase cathepsin K, a macrophage effector molecule, whose levels correlates with RA clinical disease activity ([@B129]). Lipopolysaccharide (LPS) stimulated macrophages (M1 macrophages) display a decreased TCA cycle. Moreover the mitochondrial oxidative phosphorylation pathway is coupled to the up-regulation of glucose transporter 1 (Glut1) to facilitate efficient uptake of glucose ([@B18]). ROS production is increased, partly as a consequence of reversed electron transport in mitochondria, and the accumulation of TCA cycle intermediates such as succinate, as previously described. These events promote the expression of the pro-inflammatory cytokine IL-1β by inhibiting prolyl hydroxylases and activating the transcription factor HIF-1α. Succinate has also been linked to changes in DNA methylation and associated histone proteins which in turn modulate gene expression ([@B67]). In animal models of arthritis, succinate has been shown to induce synovial angiogenesis through VEGF-dependent HIF-1α pathways ([@B59]).

In RA, ROS are thought to directly contribute to destructive and proliferative synovitis ([@B25]). High levels of ROS accumulate in the synovial fluid and peripheral blood of RA patients where they can modify (e.g., via oxidation) major components of cartilage and bone, such as collagen and hyaluronic acid, inducing bone and cartilage destruction ([@B49]; [@B16]). Moreover ROS levels positively correlate with disease activity ([@B25]) and contribute to osteoclast differentiation via RANK signaling ([@B57]).

Lipid Metabolism {#S5}
================

Recent discoveries have highlighted the role of lipid metabolism in the regulation of immune cells functions ([@B22]) and targeting lipid mediators is becoming an attractive field in autoimmune and allergic disorders ([@B62]).

It has been recently reported that the short chain fatty acids (FAs) such as acetate, propionate and butyrate are able to orchestrate several CD4^+^ T cell functions by modulating the activity of histone deacetylases (HDAC) ([@B79]) and via the peroxisome proliferator-activated receptor (PPAR) signaling ([@B4]; [@B55]; [@B17]). Lipid metabolism is also crucial for T cell activation and proliferation. Indeed, T cell activation is accompanied by the upregulation of sterol regulatory element binding protein (SREBP). Lack of SREBP by genetic inactivation is detrimental to T cells undergoing clonal expansion after activation ([@B52]).

T cells from patients with RA display increased fatty acid synthesis (FAS) leading to their increased tissue invasiveness. More specifically, reduced glycolytic flux due to PFKFB3 deficiency, promotes a shunt toward anabolic glucose utilization (increased PPP and FAS) and the up-regulation of the podosome scaffold adapter protein TKS5 (SH3PXD2A), which is involved in the formation of cell membrane protrusions ([@B124]; [@B103]). In addition, enhanced FAS causes the accumulation of cytoplasmic lipid droplets, which are necessary for T cell functions including cell growth, proliferation and for naïve to memory T cell conversion. Interestingly, restoring pyruvate level was able to replenish T cell locomotion and limit tissue-invasiveness and inflammation in non-obese diabetic (NOD) SCID mice (NSG mice) engrafted with human synovial tissue. In addition, inhibition of FAS efficiently reduced tissue inflammation, decreased the number of RANKL^+^ and IFN-γ^+^ T cells and diminished the total number of T cell infiltrating the synovial tissue ([@B103]). *De novo* FAS regulate Th17 differentiation ([@B5]). Indeed the inhibition of acetyl-CoA carboxylase (ACC) *in vitro*, using the specific inhibitor Sorafen A, leads to an impaired differentiation of Th17, favoring instead the differentiation of Foxp3^+^ Treg cells ([@B5]). Consistent with these results, we have recently shown that in the presence of lactate, at concentrations comparable to those measured in the synovial tissue, CD4^+^ T cells upregulate the *de novo* FAS, leading to increased IL-17 and reduced cell motility ([@B89]). Interestingly, these events were restored after treating CD4^+^ T cells with a range of FAS inhibitors and reducing the lactate-induced NADPH levels ([@B89]).

While *de novo* FAS has been shown to play an important role in effector CD4^+^ T cell functions, cholesterol metabolism is involved in the regulation of the anti-inflammatory response in human CD4^+^ T cells ([@B84]). Inhibition of the cholesterol biosynthesis pathway with atorvastatin or 25-hydroxycholesterol during switching from IFNγ^+^ to IL-10^+^ showed a specific block in immune resolution, defined as a significant decrease in c-Maf/IL-10 expression ([@B84]).

Metabolomics profiling has shown alterations in the lipid metabolism in RA versus OA FLS. In line with this evidence, choline and choline like transporter (CTL)1 (high-affinity) and CTL2 (low affinity), were found to be highly expressed by synovial RA FLS ([@B1]; [@B118]) and their functional inhibition promoted FLS cell death ([@B100]). Supporting these findings, positron emission tomography (PET) scanning with ^11^C-choline showed increased uptake in inflamed arthritic joints ([@B100]). Further studies are needed to understand the mechanisms linking lipid metabolism to FLS effector functions and subset differentiation in RA.

Tanscription Factors as Metabolic Sensors {#S6}
=========================================

Catabolic and anabolic pathways are regulated by specific transcription factors which act as metabolic sensors. In this context, 5′ AMPK is a redox sensor, being activated by increased AMP:ATP ratios ([@B105]). AMPK modulates several metabolic functions, including glucose uptake, mitochondrial biogenesis and lipid metabolism, as well as cellular functions (i.e., transcriptional activity and cell cycle). Therapeutic AMPK activation was reported to suppress experimental arthritis. Moreover, methotrexate-induced activation of AMPK-dependent pathway has been shown to protect the vasculature against inflammation ([@B51]; [@B123]; [@B111]). AMPK activation is myristoylation dependent. Notably, RA T cells display a defect in N-myristoyltransferase (NMT) function, which prevents AMPK activation and enables mTORC1 signaling activation, resulting in pro-inflammatory Th1 and Th17 differentiation. NMT1 loss of function experiments induced an inflammatory response both *in vitro* and *in vivo*; by contrast, NMT1 overexpression restored AMPK activation and suppressed synovial inflammation ([@B119]).

Finally, metformin, an anti-diabetic drug, which indirectly activates AMPK, has been shown to mitigate disease in mouse models of arthritis ([@B107]) *via* the inhibition of mTOR pathway, the suppression of NF-κB-mediated inflammatory cytokine production as well as enhanced autophagic flux ([@B123]).

Together with AMPK, mTOR is a central integrator of environmental signals and nutrient availability with cellular functions ([@B28]; [@B85]; [@B91]). Indeed, aberrant mTOR activation is associated with cellular senescence, and rapamacyin, the mTOR complex 1 inhibitor, has been investigated as a therapeutic agent to treat degenerative, autoimmune and hyperproliferative diseases ([@B83]). The ability of mTOR to integrate nutrient supply, bioenergetics and T cell functions, makes it a promising target for therapeutic intervention to suppress abnormal T cell differentiation during the early stages of RA ([@B83]).

Adipo-Cytokines {#S7}
===============

A link between the neuroendocrine and immune systems has been shown to contribute to the pathogenesis of several immune mediated inflammatory disorders ([@B14]; [@B87]). In this context adipo-cytokines, such as leptin and adiponectin, hormones secreted mainly by the adipose tissue, have been shown to play a role in RA pathogenesis ([@B41]; [@B95]). For instance, it has been shown that *ob/ob* mice develop resistance to experimental antigen-induced arthritis compared to wild-type mice ([@B11]). In addition a decrease in serum leptin concentration following fasting, limited CD4^+^ activation, promoted a shift toward Th2-type cytokine secretion, and improved clinical disease in RA patients ([@B33]). Leptin can also directly modulate chondrocyte biology. Indeed, leptin induces, in combination with IFN-γ and IL-1, nitric oxide synthases (NOS) type II activation in cultured chondrocytes ([@B75]). These events promote pro-inflammatory cytokine production in joint cartilage, causing chondrocyte apoptosis, metalloproteases activation and consequently inflammation ([@B77]). However there is conflicting evidence regarding the role of leptin in RA ([@B112]). Some studies have found elevated leptin in serum from RA patients ([@B9]; [@B121]; [@B127]) in particular in patients with erosive RA ([@B110]; [@B73]). Conversely other reports have showed no difference in serum leptin levels between RA patients and healthy controls ([@B42]; [@B45]; [@B74]). Leptin has also been detected in RA synovial fluid and tissue. A study by [@B102] reported that serum and synovial fluid leptin levels were higher in RA patients when compared to controls, with positive correlation with disease activity. Another study showed instead a negative correlation between leptin synovial fluid levels and bone erosions. In addition, leptin levels were higher in the serum than in the synovial fluid suggesting that leptin may be consumed in the joints and have a protective role against erosions ([@B9]).

Similar to leptin, adiponectin has also been suggested to play a role in the pathogenesis of RA, though again results are inconsistent. Adiponectin is a 28--30 kDa collagen-like protein predominantly secreted by adipocytes. In some studies, increased levels of adiponectin were found in synovial fluid and serum of patients with RA ([@B99]; [@B76]) and were associated with the production of pro-inflammatory mediators and arthritis ([@B30]). In other studies, serum adiponectin showed no association or a negative correlation with disease activity in RA ([@B101]; [@B92]; [@B127]). In the DBA/1 mouse model of collagen-induced arthritis, adiponectin treatment significantly alleviated the severity of arthritis together with a decrease in the expression of pro-inflammatory cytokines such as TNF-α and IL-1, and the reduction of metalloproteinase (MMP)-3 in synovial tissues ([@B58]). These latter findings suggest that in RA the role of adiponectin is anti-inflammatory rather than pro-inflammatory.

Treatments Affecting Metabolic Signaling Pathways in RA {#S8}
=======================================================

Several drugs currently in use to treat RA affect metabolic signaling pathways. Glucocorticoids for example, inhibit the glycolytic enzyme fructose 2,6-bisphosphate in rat tymocytes and regulate respiratory rate in peripheral blood mononuclear cells from patients with rheumatic diseases ([@B70]; [@B56]). Methotrexate's anti-inflammatory effects depend on the modulation of purine or pyrimidine nucleotide metabolism ([@B21]). Similarly, biologic disease modifying anti rheumatic drugs (DMARDs) can modulate specific metabolic pathways. For example, anti-TNF-α and JAK inhibitor (i.e. tofacitinib) treatments decrease glycolysis in RA synovium ([@B7]; [@B63]).

In the context of tofacitinib, it significantly increased oxidative phosphorylation, mitochondrial respiration in RA FLS, coupled with a decrease in glycolysis and several key glycolytic enzymes such as HK2, glycogen synthase kinase 3α (GSK-3α), lactate dehydrogenase A, and HIF-1α both in RA FLS and synovial explants ([@B63]). It would be interesting to evaluate if these events are associated with reduced lactate levels and impaired lactate/STAT3 signaling as we have recently shown ([@B89]).

The anti IL-6 receptor antibody tocilizumab decreases oxidative stress in RA leucocytes ([@B93]). Over-expression of HK2 has been associated with resistance to rituximab (anti-CD20) in aggressive lymphoma, whilst the impact of rituximab on immune cell metabolism in RA patients is still unknown ([@B38]).

Conclusion and Further Perspectives {#S9}
===================================

The tissue microenvironment plays a pivotal role in the pathology of inflammatory diseases such as RA. A lack of nutrients, low oxygen concentrations, accumulation of metabolic intermediates as well as unbalanced metabolic pathways drive the local immune response in such a way as to exacerbate chronic inflammation ([Figure 1](#F1){ref-type="fig"}).

Immunometabolism studies have recently highlighted the possibilty of targeting metabolic pathways, metabolites, transcription factors and enzymes that are altered in RA ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Several drugs currently in use to treat RA affect metabolic signaling pathways. However, we are now in a position from which we can consider developing therapies to specifically target pathogenetically relevant metabolic pathways. For example, targeting specific metabolic pathways has been demonstrated to reduce inflammation both *in vitro* and *in vivo* models of arthritis ([@B123]; [@B7]; [@B72]; [@B103]; [@B12]). In addition, targeting metabolic intermediates such as lactate ([@B90]; [@B15]) or succinate ([@B60]), is also becoming an attractive possibility. Animal models remain a crucial tool for preclinical screening of new therapeutics in pharmaceutical development. However, potential therapeutics, which have been shown to be safe and effective in animal studies, have in certain cases failed when tested in humans. Further knowledge on human immunology and additional development of animal models that bear more resemblance to the human condition are needed ([@B44]; [@B6]). Another important area of investigation is the impact of sex and gender on RA immunometabolism. Prevalence of RA is higher in women than in men ([@B116]). This is partly ascribed to the effect of sex hormones on the immune system and their interaction with environmental and genetic factors ([@B2]). Estrogenic control of mitochondrial function and glycolysis metabolism has been studied ([@B13]; [@B54]), however what are the sex-based differences in RA cell immunometabolism is still unknown and needs further investigation.

###### 

Potential metabolic therapeutic targets in RA.

  -------------------------------------------------------------------------------------
  Cells                   Defective metabolic Pathway   Potential therapeutic targets
  ----------------------- ----------------------------- -------------------------------
  T cell                  Glycolysis (−)\               PFKFB3\
                          PPP (+)\                      G6PD\
                          Lipid (+)                     FASN\
                                                        Lactate/SLC5A12\
                                                        AMPK/mTOR

  Monocytes/macrophages   Glycolysis (+)\               PKM2\
                          TCA (+)\                      HIF\
                          AMPK (−)                      Succinate/GPR91\
                                                        Lactate/MCT1 and 4

  Fibroblasts             Glycolysis (+)\               GLUT1\
                          Lipid (+)                     HK2\
                                                        PFKFB3\
                                                        Choline/Chokα

  Dendritic cells         Glycolysis (+)                HK2\
                                                        iNOS\
                                                        AKT/mTOR
  -------------------------------------------------------------------------------------

AMPK, adenosine monophosphate-activated protein kinase; Chokα, choline kinase alpha; FAS, fatty acid synthase; G6PD, glucose-6-phosphate dehydrogenase; G6PI, glucose 6 phosphate isomerase; HK2, hexokinase 2; iNOS, inducible nitric oxide synthase; HIF-1α, hypoxia-inducible factor 1-alpha; MCT, monocarboxylate transporter; mTOR, mammalian target of rapamycin; PFKFB3, 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase; PKM2, pyruvate kinase muscle isozyme 2; PPP, pentose phosphate pathway; SLC5A12, solute carrier 5A12; (−) decreased, (+) enhanced.

Correlation studies between serum metabolites and synovial and blood biomarkers suggests that NMR and mass-spectrometry may be promising tools for predicting specific pathogenic pathways altered in RA ([@B128]; [@B130]; [@B71]). In addition they may be useful in the future to to identify which RA patients are at higher risk to develop artheroslerosis. Metabolomics profiles in serum, plasma, or urine do not necessarily correlate with joint metabolism as well as synovial fluid metabolites may not identify metabolic pathway alterations in the synovial tissues.

Further studies are needed to better determine whether specific metabolic signatures can be used to stratify patients with RA in terms of outcome, disease stage and response to therapy. Single cell RNA-seq techniques will be of help to shed light on metabolic pathways used by specific immune cells (i.e., macrophages, lymphocytes, fibroblast) in the context of the RA inflammatory environment.

Advanced RNA-seq techniques are also developing. In this context, the droplet-based single-cell RNA-seq has recently been shown to be a promising tool for cellular profiling allowing the analysis of thousands of individual cells simultaneously by encapsulating them in tiny droplets ([@B97]). Similarly single cell metabolomic analysis will facilitate the identification of new biomarkers and the development of novel therapeutic molecules targeting abnormal metabolic signaling pathways at single cell level without dampening homeostatic immune responses.
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